Babak, Czech Republic
Babak, Czech Republic

Time filter

Source Type

Al-Sahmani M.,Faculty Hospital Brno | Al-Sahmani M.,Faculty Hospital | Al-Sahmani M.,Babak Myeloma Group | Trnavska I.,Faculty Hospital Brno | And 16 more authors.
Neoplasma | Year: 2011

Multiple myeloma (MM) is a hematological malignancy caused by clonal proliferation of malignant plasma cells (PC). The aim of the work is to determine prognostic significance of morphological subtypes of PC in relation to overall treatment response, long-term survival and other conventional prognostic parameters. One hundred and thirty-nine newly diagnosed MM patients who underwent autologous transplantation in clinical trials conducted in one center were included. Percentual representation of subtypes of plasma cells in bone marrow was measured based on progressive analysis of nucleolus, nuclear chromatin and ratio of nuclei to the volume of cytoplasm (N/C ratio) creating 8 subtypes P000-P111 and four subclassifications of cells. Mature plasma cells (P000, P001) were found in 42.4% of patients; proplasmocytes I (P010, P011, P100) in 38.1% of patients, and proplasmocytes II (P101, P110) in 19.4% of patients. Patients who reached treatment response after autologous transplantation had statistically significant lower frequency of mature plasma cells than patients with no treatment response (median 24.0% vs. 36.0%; p=0.032). Patients with mature plasma cells of subtype P000 < 10% had significantly shorter overall survival than patients with value P000 ≥ 37% (median 46.8 months vs. 77.8 months; p = 0.020). Patients with proplasmocytes II subtype P110 < 3% had longer time to progression than patients with subtype P110 ≥ 31% (median 54.6 months vs. 22.4 months; p=0.045). Our work brings valuable prognostic information and correlation with other prognostic factors as well as total treatment response and survival in MM patients who underwent autologous transplantation.


Kryukov F.,Babak Myeloma Group | Nemec P.,Babak Myeloma Group | Dementyeva E.,Babak Myeloma Group | Kubiczkova L.,Babak Myeloma Group | And 10 more authors.
Leukemia and Lymphoma | Year: 2013

In multiple myeloma (MM), biologic complexity originates from complex oncogenic processes involving somatic acquisition of myriad mutations coupled with genetic variability within the host. This pathogenically determined molecular heterogeneity predetermines clinical intricacy. In this study, we performed gene expression profiling (GEP) focusing on centrosome-related genes to determine the molecular heterogeneity for centrosome-associated genes in patients with MM. We identified the gene pattern with an impact on myeloma pathogenesis. According to expression tendency, three subgroups of patients were established. The revealed molecular signature is related to overall survival as well as to clinical parameters and the International Staging System. Associations with integral clinical parameters allow us to proclaim the impact of the revealed functional gene set in MM genesis. We believe that future investigation of this molecular heterogeneity will help to refine the broad prognoses offered by present-day established systems and even sub-stratify them. © 2013 Informa UK, Ltd.

Loading Babak Myeloma Group collaborators
Loading Babak Myeloma Group collaborators